The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...
Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to ...
Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback